Compare BTMD & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | TELA |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 31.4M |
| IPO Year | 2021 | 2019 |
| Metric | BTMD | TELA |
|---|---|---|
| Price | $0.84 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $2.22 | $2.00 |
| AVG Volume (30 Days) | 84.3K | ★ 120.4K |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $192,219,000.00 | $80,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.95 | $8.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.93 | $0.50 |
| 52 Week High | $2.90 | $1.50 |
| Indicator | BTMD | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 37.34 |
| Support Level | N/A | $0.60 |
| Resistance Level | $1.24 | $0.75 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 19.03 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.